Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

NCT05176665 is registered in ClinicalTrials.gov with Shanghai EpimAb Biotherapeutics Co., Ltd. as lead sponsor.

NCT NCT05176665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05176665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 21, 2021
Completion date
December 31, 2025
Enrollment
152 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastrointestinal carcinoid tumor, neoplasm metastasis, neoplasms